ALNY vs NKE · P/E 76, rev $1.29B vs P/E 35, rev $46.40B
Alnylam Pharmaceuticals Inc (ALNY) versus Nike Inc (NKE) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Nike Inc (NKE) is a footwear & accessories company listed on US. It is led by Elliott J. Hill.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported NKE revenue for 2026-05-31 was $46.40B. Net income was $3.11B. NKE currently screens at market cap $110.14B and trailing P/E 34.6.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. NKE currently screens at market cap $110.14B and trailing P/E 34.6.
Not investment advice. Open the ALNY and NKE stock pages for the full models.
Not investment advice.